# Emergent BioSolutions Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/EBS/emergent-biosolutions-reports-first-quarter-2026-financial-results
Ticker: EBS
Company: Emergent BioSolutions
Source: Emergent BioSolutions
Published: 2026-04-30 20:30 EST
Original Source URL: https://investors.emergentbiosolutions.com
## Summary

First Quarter 2026 Total Revenues of $156.1 million First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.

## Article Body
First Quarter 2026 Total Revenues of $156.1 million First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.
## Recent Company News
- 2026-05-28 20:01 EST — [Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-64-5-million-contract-modification-for-batr-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy) — Source: Emergent BioSolutions
- 2026-05-20 11:30 EST — [Emergent BioSolutions to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/EBS/emergent-biosolutions-to-participate-in-upcoming-investor-conferences) — Source: Emergent BioSolutions
- 2026-05-18 12:59 EST — [Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-saudi-food-and-drug-authority-approval-for-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live) — Source: Emergent BioSolutions
- 2026-04-30 20:30 EST — [Emergent BioSolutions Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/EBS/emergent-biosolutions-reports-first-quarter-2026-financial-results) — Source: Emergent BioSolutions
- 2026-04-30 11:55 EST — [Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox](https://biopharmsignal.com/news/EBS/emergent-biosolutions-receives-approval-from-singapore-health-sciences-authority-for-expanded-indication-of-acam2000r-smallpox-and-mpox-vaccinia-vaccine-live-to-include-mpox) — Source: Emergent BioSolutions
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)